IN2014MN01547A - - Google Patents

Info

Publication number
IN2014MN01547A
IN2014MN01547A IN1547MUN2014A IN2014MN01547A IN 2014MN01547 A IN2014MN01547 A IN 2014MN01547A IN 1547MUN2014 A IN1547MUN2014 A IN 1547MUN2014A IN 2014MN01547 A IN2014MN01547 A IN 2014MN01547A
Authority
IN
India
Prior art keywords
compounds
disclosed
methods
agents
host
Prior art date
Application number
Other languages
English (en)
Inventor
Vidya Ramdas
Advait Arun Joshi
Moloy Manoj Banerjee
Amit Kumar Das
Deepak Sahebrao Walke
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN1547MUN2014 priority Critical patent/IN2014MN01547A/en
Publication of IN2014MN01547A publication Critical patent/IN2014MN01547A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN1547MUN2014 2012-02-10 2013-02-08 IN2014MN01547A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN1547MUN2014 IN2014MN01547A (ja) 2012-02-10 2013-02-08

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN147KO2012 2012-02-10
IN1017KO2012 2012-09-04
IN1547MUN2014 IN2014MN01547A (ja) 2012-02-10 2013-02-08
PCT/IB2013/051062 WO2013118097A1 (en) 2012-02-10 2013-02-08 Antiviral compounds with a dibenzooxaheterocycle moiety

Publications (1)

Publication Number Publication Date
IN2014MN01547A true IN2014MN01547A (ja) 2015-05-08

Family

ID=54259033

Family Applications (2)

Application Number Title Priority Date Filing Date
IN1547MUN2014 IN2014MN01547A (ja) 2012-02-10 2013-02-08
IN1548MUN2014 IN2014MN01548A (ja) 2012-02-10 2013-02-09

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN1548MUN2014 IN2014MN01548A (ja) 2012-02-10 2013-02-09

Country Status (14)

Country Link
US (2) US9073943B2 (ja)
EP (2) EP2812326A1 (ja)
JP (1) JP6034883B2 (ja)
KR (1) KR20140129034A (ja)
CN (1) CN104136433B (ja)
AU (2) AU2013217224B2 (ja)
BR (1) BR112014019584A8 (ja)
CA (2) CA2862755A1 (ja)
IN (2) IN2014MN01547A (ja)
MX (1) MX2014009546A (ja)
NZ (2) NZ628515A (ja)
SG (2) SG11201404475TA (ja)
WO (2) WO2013118097A1 (ja)
ZA (1) ZA201405490B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140053166A (ko) 2011-07-09 2014-05-07 선샤인 레이크 파르마 컴퍼니 리미티드 C형 간염 바이러스 억제제로서 스피로 화합물
CA2862755A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP3021845A1 (en) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
CN104725365B (zh) * 2013-12-23 2019-02-26 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR20170115940A (ko) * 2016-04-08 2017-10-18 롬엔드하스전자재료코리아유한회사 유기 전계 발광 화합물 및 이를 포함하는 유기 전계 발광 소자
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
UY38705A (es) * 2019-05-23 2020-12-31 Irbm S P A Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b
CN114605310B (zh) * 2022-04-09 2024-05-07 都创(上海)医药科技股份有限公司 一种氮杂五元环并三元环羧酸酯衍生物及其盐的合成方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
JPWO2005012284A1 (ja) 2003-07-31 2007-09-27 大正製薬株式会社 4,5−ジヒドロナフト[1,2−b]チオフェン誘導体
SI1670744T1 (sl) 2003-09-19 2010-11-30 Janssen Pharmaceutica Nv fenoksialkil tio fenoksiocetne kisline in analogi
CA2551056A1 (en) 2003-11-07 2005-05-19 F. Hoffmann-La Roche Ag Benzo[b][1,4]dioxepine derivatives
GB0421908D0 (en) 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
GB0501964D0 (en) 2005-01-31 2005-03-09 Arrow Therapeutics Ltd Chemical compounds
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
JP2009508835A (ja) 2005-09-16 2009-03-05 アロー セラピューティクス リミテッド ビフェニル誘導体及びc型肝炎の治療におけるその使用
ZA200805227B (en) 2005-12-12 2009-11-25 Genelabs Tech Inc N-(5-memebered heteroarmatic ring)-amido anti-viral compounds
CA2633541A1 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
WO2007082554A1 (en) 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA200970375A1 (ru) 2006-10-13 2009-10-30 Президио Фармасьютикалз, Инк. Соединения и способы лечения вируса гепатита с
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010510245A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス化合物
WO2008064218A2 (en) 2006-11-21 2008-05-29 Smithkline Beecham Corporation Amido anti-viral compounds
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20090317360A1 (en) 2007-06-12 2009-12-24 Genelabs Technologies, Inc. Anti-viral inhibitors and methods of use
BRPI0813952A2 (pt) 2007-06-29 2017-05-09 Gilead Sciences Inc derivados de purina e seu emprego como moduladores e receptor 7 semelhante ao dobre de sino
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
WO2009034390A1 (en) 2007-09-14 2009-03-19 Arrow Therapeutics Limited Heterocyclic derivatives and their use in treating hepatitis c
CN104016970A (zh) 2007-10-10 2014-09-03 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
PT2250163E (pt) 2008-02-12 2012-06-01 Bristol Myers Squibb Co Inibidores do vírus da hepatite c
US8093243B2 (en) 2008-02-12 2012-01-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2242752T3 (pl) 2008-02-13 2012-12-31 Bristol Myers Squibb Co Imidazolilobifenyloimidazole jako inhibitory wirusa zapalenia wątroby typu c
SI2937350T1 (en) 2008-04-23 2018-05-31 Gilead Sciences, Inc. 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20110217265A1 (en) 2008-09-23 2011-09-08 Glenn Jeffrey S Screening for Inhibitors of HCV Amphipathic Helix (AH) Function
NZ593808A (en) 2008-12-03 2014-04-30 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
PE20120257A1 (es) 2009-02-10 2012-03-29 Gilead Sciences Inc Analogos carba-nucleosidicos para tratamiento antiviral
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
WO2010111534A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
GEP20146134B (en) 2009-03-27 2014-08-11 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3626716A1 (en) 2009-05-13 2020-03-25 Gilead Pharmasset LLC Antiviral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2462136A1 (en) 2009-08-07 2012-06-13 Janssen R&D Ireland Phenyl ethynyl derivatives as hepatitis c virus inhibitors
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
SG181614A1 (en) 2009-12-24 2012-07-30 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
CN102858157A (zh) 2010-03-04 2013-01-02 埃南塔制药公司 作为hcv复制的抑制剂的组合药物活性剂
ES2558554T3 (es) 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2011151652A1 (en) 2010-06-03 2011-12-08 Arrow Therapeutics Limited Benzodiazepine compounds useful for the treatment of hepatitis c
WO2011151651A1 (en) 2010-06-03 2011-12-08 Arrow Therapeutics Limited Benzodiazepine compounds useful for the treatment of hepatitis c
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011156543A2 (en) 2010-06-09 2011-12-15 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
CN103153986B (zh) 2010-08-04 2014-11-05 百时美施贵宝公司 丙型肝炎病毒抑制剂
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2606041A2 (en) 2010-08-17 2013-06-26 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
MX2013002927A (es) 2010-09-24 2013-05-30 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
KR20140001879A (ko) 2010-09-29 2014-01-07 머크 샤프 앤드 돔 코포레이션 C형 간염 바이러스 감염을 치료하기 위한 테트라시클릭 인돌 유도체
WO2012041227A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds for treating hepatitis c viral infection
CA2817840A1 (en) 2010-11-17 2012-05-24 Gilead Sciences, Inc. Antiviral compounds
CA2862755A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety

Also Published As

Publication number Publication date
MX2014009546A (es) 2015-10-29
JP2015510512A (ja) 2015-04-09
CN104136433B (zh) 2016-05-04
AU2013217224B2 (en) 2017-04-06
AU2013217224A1 (en) 2014-08-21
AU2013217229A1 (en) 2014-08-21
CA2862755A1 (en) 2013-08-15
BR112014019584A8 (pt) 2017-07-11
WO2013118097A1 (en) 2013-08-15
EP2812326A1 (en) 2014-12-17
IN2014MN01548A (ja) 2015-05-08
US20150010505A1 (en) 2015-01-08
KR20140129034A (ko) 2014-11-06
CN104136433A (zh) 2014-11-05
US9073943B2 (en) 2015-07-07
BR112014019584A2 (ja) 2017-06-20
ZA201405490B (en) 2015-10-28
US9073942B2 (en) 2015-07-07
NZ628445A (en) 2016-05-27
US20150010504A1 (en) 2015-01-08
JP6034883B2 (ja) 2016-11-30
EP2812327A1 (en) 2014-12-17
WO2013118102A1 (en) 2013-08-15
SG11201404365SA (en) 2014-10-30
CA2862330A1 (en) 2013-08-15
SG11201404475TA (en) 2014-08-28
NZ628515A (en) 2016-06-24
AU2013217229B2 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
IN2014MN01547A (ja)
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
MX2022013596A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2018010805A (es) Agentes antivirales contra la hepatitis b.
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703064A (en) Inhibitors of hepatitis c virus
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
MX2012008221A (es) Inhibidores de virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
HK1166788A1 (ja)
TN2012000358A1 (en) Hepatitis c virus inhibitors
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
PH12015501560A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
IN2012DN01855A (ja)
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
WO2013059278A3 (en) Hepatitis c virus inhibitors
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c